Events were counted once, on the basis of onset during each 2-week interval. We calculated proportion of patients who had the adverse event during each interval using total number of patients remaining in the trial during each time interval.Panel: Research in context Systematic review We searched PubMed from Jan 1, 2004, to June 22, 2012  with  the terms “randomised clinical trials,” “exenatide,” and “liraglutide”. Non-English, review articles, meta-analyses,  and non-randomised clinical trial references were manually excluded but no clinical trials were excluded on the basis of duration of therapy. We identiﬁ  ed one study of a direct  comparison between liraglutide and exenatide twice daily. 17  DURATION-6 is the only direct comparison of the eﬃ   cacy and  safety of exenatide once weekly with those of liraglutide. Interpretation Once-daily administration of liraglutide 1·8 mg resulted in greater reductions in HbA 1c and bodyweight than did